EYPT · Company research
EyePoint, Inc. Common Stock (EYPT): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
21records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD | EyePoint announced that LUCIA, its second Phase 3 clinical trial of DURAVYU for wet AMD treatment, failed to meet its primary endpoint of non-inferiority in visual acuity versus aflibercept control. However, the drug demonstrated visual improvement and met key secondary endpoints including a 38% reduction in treatment burden and strong anatomic control. The company plans to conduct additional analyses and remains focused on its Phase 3 DME program with data expected in Q4 2027. | View source ↗ | GlobeNewswire Inc. | Oct 19, 2026 | bearish | -1 | 1 |
| Here's Why You Should Add EYPT Stock to Your Portfolio Now | EyePoint (EYPT) reported mixed results from its LUGANO wet AMD study, with Duravyu failing to meet the primary endpoint but showing encouraging secondary endpoint results. The company expects LUCIA study data in Q4 2026 and has completed enrollment in two phase III DME studies with results expected in Q4 2027. EYPT shares have declined 83.5% year-to-date despite a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.5 | 1 |
| Here's Why You Should Add EYPT Stock to Your Portfolio Now - Yahoo Finance | Here's Why You Should Add EYPT Stock to Your Portfolio Now Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| FEDERATED HERMES, INC. Adds EyePoint Inc (EYPT) Shares -- Stock Looks 708% Overvalued on GF Value - GuruFocus | FEDERATED HERMES, INC. Adds EyePoint Inc (EYPT) Shares -- Stock Looks 708% Overvalued on GF Value GuruFocus | View source ↗ | GuruFocus | Oct 14, 2026 | neutral | 0 | 0.6 |
| OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why - Stocktwits | OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why Stocktwits | View source ↗ | Stocktwits | Oct 8, 2026 | neutral | 0 | 0.6 |
| EyePoint, Inc (NASDAQ: EYPT) Share Price, EYPT Stock News, EYPT Share Price & Updates - Kalkine | EyePoint, Inc (NASDAQ: EYPT) Share Price, EYPT Stock News, EYPT Share Price & Updates Kalkine | View source ↗ | Kalkine | Oct 8, 2026 | neutral | 0 | 0.6 |
| Five parties report an EyePoint (EYPT) stake but disclaim ownership of shares held by Managed Funds. - Stock Titan | Five parties report an EyePoint (EYPT) stake but disclaim ownership of shares held by Managed Funds. Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT | Pomerantz LLP is investigating securities fraud claims against EyePoint, Inc. following the company's announcement that its Phase 3 clinical trial for DURAVYU failed to meet its primary endpoint against Regeneron's Eylea. The stock plummeted 66.98% to $4.87 per share on August 17, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bearish | -0.5 | 1 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT | Pomerantz LLP is investigating securities fraud claims against EyePoint, Inc. following the company's announcement that its Phase 3 clinical trial for DURAVYU failed to meet its primary endpoint against Regeneron's Eylea. The stock plummeted 66.98% to $4.87 per share on August 17, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bearish | -0.5 | 1 |
| $EYPT stock is down 8% today. Here's what we see in our data. - Quiver Quantitative | $EYPT stock is down 8% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 28, 2026 | neutral | 0 | 0.6 |
| EyePoint (EYPT) Stock Sees Fair Value Cut After Split Analyst Revisions On LUGANO - Yahoo Finance | EyePoint (EYPT) Stock Sees Fair Value Cut After Split Analyst Revisions On LUGANO Yahoo Finance | View source ↗ | Yahoo Finance | Sep 4, 2026 | neutral | 0 | 0.6 |
| $EYPT stock is down 10% today. Here's what we see in our data. - Quiver Quantitative | $EYPT stock is down 10% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 27, 2026 | neutral | 0 | 0.6 |
| EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky - PR Newswire | EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky PR Newswire | View source ↗ | PR Newswire | Aug 26, 2026 | neutral | 0 | 0.6 |
| EyePoint (EYPT) CFO moves 139K shares into family and annuity trusts - Stock Titan | EyePoint (EYPT) CFO moves 139K shares into family and annuity trusts Stock Titan | View source ↗ | Stock Titan | Aug 24, 2026 | neutral | 0 | 0.6 |
| EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT) - Business Wire | EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT) Business Wire | View source ↗ | Business Wire | Aug 21, 2026 | neutral | 0 | 0.6 |
| EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals - PR Newswire | EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals PR Newswire | View source ↗ | PR Newswire | Aug 20, 2026 | neutral | 0 | 0.6 |
| EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal - Yahoo Finance | EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal Yahoo Finance | View source ↗ | Yahoo Finance | Aug 18, 2026 | neutral | 0 | 0.6 |
| EYPT Stock Crashes On Duravyu Data But Catalysts Loom - StocksToTrade | EYPT Stock Crashes On Duravyu Data But Catalysts Loom StocksToTrade | View source ↗ | StocksToTrade | Aug 18, 2026 | neutral | 0 | 0.6 |
| EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate - Yahoo Finance | EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate Yahoo Finance | View source ↗ | Yahoo Finance | Aug 17, 2026 | neutral | 0 | 0.6 |
| EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate - TradingView | EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate TradingView | View source ↗ | TradingView | Aug 17, 2026 | neutral | 0 | 0.6 |
| EYPT Forecast — Price Target — Prediction for 2027 - TradingView | EYPT Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.